These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37933625)
1. Obstructive hypertrophic cardiomyopathy: a review of new therapies. Mehra N; Ali AH; Desai MY Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625 [TBL] [Abstract][Full Text] [Related]
2. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Mathai S; Williams L Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related]
11. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents. Hajj Ali A; Mehra N; Desai MY Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068 [TBL] [Abstract][Full Text] [Related]
12. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620 [TBL] [Abstract][Full Text] [Related]
13. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. Packard E; de Feria A; Peshin S; Reza N; Owens AT Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823 [TBL] [Abstract][Full Text] [Related]
14. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study. Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645 [TBL] [Abstract][Full Text] [Related]
15. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy. Chase Cole J; Benvie SF; DeLosSantos M Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915 [TBL] [Abstract][Full Text] [Related]
16. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. Reyes KRL; Bilgili G; Rader F Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099 [TBL] [Abstract][Full Text] [Related]
17. Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy. Patel J; Wang A; Naidu SS; Frishman WH; Aronow WS Cardiol Rev; 2023 Oct; ():. PubMed ID: 37881953 [TBL] [Abstract][Full Text] [Related]
18. The Role of the Submitral Apparatus in Hypertrophic Obstructive Cardiomyopathy. Tao J; Duan F; Long J; Meng Q; Zhang B; Zhu Z; Wang H J Am Soc Echocardiogr; 2023 Feb; 36(2):133-145. PubMed ID: 36191671 [TBL] [Abstract][Full Text] [Related]